References
- Bunnage ME. Getting pharmaceutical R&D back on target. Nat Chem Biol. 2011;7:335–339.
- Morgan P, Van der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Disc Today. 2012;17:419–424.
- Vincent FB, Loria P, Pregel M, et al. Developing predictive assays: the phenotypic screening ‘rule of 3’. Sci Transl Med. 2015;7:293ps15.
- Jones LH Chemogenomic screening identifies small molecule up-regulators of MBNL1 for the treatment of type 1 myotonic dystrophy. 251st ACS National Meeting & Exposition; 2016 Mar 14; San Diego, CA.
- Jones LH. Cell permeable affinity- and activity-based probes. Future Med Chem. 2015;7:2131–2141.
- Savitski MM, Reinhard FB, Franken H, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.
- Palchaudhuri R, Hergenrother PJ. Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. ACS Chem Biol. 2011;6:21–33.
- Zhang Y, Berka V, Song A, et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest. 2014;124:2750–2761.
- Chindelevitch L, Ziemek D, Enayetallah A, et al. Causal reasoning on biological networks: interpreting transcriptional changes. Bioinformatics. 2012;28:1114–1121.
- Bunnage ME, Chekler ELP, Jones LH. Target validation using chemical probes. Nat Chem Biol. 2013;9:195–199.
- Chekler ELP, Pellegrino JA, Lanz TA, et al. Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem Biol. 2015;22:1588–1596.
- Xu H, Hett EC, Gopalsamy A, et al. A library approach to rapidly discover photoaffinity probes of the mRNA decapping scavenger enzyme DcpS. Mol BioSyst. 2015;11:2709–2712.